Takeda Pharmaceutical Company Limited (TAK) reported Q3 FY2025 results on January 29, 2026, with revenue down 3.3% year-over-year at constant exchange rates due to VYVANSE’s loss of exclusivity. Growth and launch products rose 6.7% at CER and now account for 52% of revenue, helping offset declines. Key drivers included Entyvio (+7.4%), Livtencity (+43.6%), and Qdenga (+22.1%), underscoring how new products are cushioning the impact of VYVANSE’s 45.7% drop.

Financially, Takeda posted Q3 YTD revenue of ¥3,411.2 billion, core operating profit down 3.4% to ¥971.6 billion, and reported operating profit up 1.2% to ¥422.4 billion. Cash flow remained strong, with operating cash flow up 15.8% to ¥966.9 billion and adjusted free cash flow up 10.1% to ¥625.9 billion. Takeda is preparing to launch three transformative medicines—Oveporexton, Rusfertide, and Zasocitinib—between late 2026 and early 2027, while accelerating late-stage programs in gastrointestinal, neuroscience, and oncology.

Takeda announced the U.S. launch of GAMMAGARD LIQUID ERC, a ready-to-use immunoglobulin therapy for primary immunodeficiency (PI) patients aged two and older. The therapy can be administered intravenously or subcutaneously without reconstitution, easing treatment for patients and providers. The product features Enhanced Removal Capability to lower IgA levels and is available in 5g/50mL and 10g/100mL vials. While not specifically indicated for IgA sensitivity, it may suit some PI patients, though risks such as thrombosis, renal dysfunction, and hypersensitivity remain.

Takeda Pharmaceutical Company Limited (NYSE:TAK) is a top-20 global, R&D-driven biopharmaceutical company headquartered in Japan, focusing on discovering, developing, and manufacturing innovative medicines. Key areas of focus include oncology, rare diseases, neuroscience, gastroenterology (GI), plasma-derived therapies, and vaccines.

Read more at Yahoo Finance: Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026?